Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial

This randomised Phase II trial (n=199) found nab-paclitaxel was not superior to paclitaxel for progression-free survival (median 3.4 months vs 3.0 months; HR 0.92; 90% CI 0.68-1.23; P=0.31) and was associated with more toxicity.


JAMA Oncology